Personalized immune cell therapy for solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment that uses your own immune cells to fight non-small cell lung cancer. It aims to create a personalized therapy based on your tumor and blood samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have non-small cell lung cancer at stage I, II, or III.
- You need to be willing to give a tumor sample and blood samples for the study.
- You must be able to attend follow-up visits for additional blood draws if needed.
- You cannot have any active infections or health issues that might make sampling unsafe.
- You should not have had another type of cancer in the past that could confuse the results.
- You cannot be taking strong immune-suppressing drugs (like high-dose steroids) unless they are part of your lung cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests a personalized cell therapy (tumor polypeptide DC-CTL) for adults with solid tumors such as colorectal, lung, or breast cancer. The goal is to see if infusing your own immune cells trained to attack cancer can help control the disease.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.